Genomics start-up Human Longevity has seen a further fall in its valuation, with its latest funding round putting its value at $310m, a fall of 80% from its estimated $1.6bn valuation in early 2017. The company seeks to pull in $25m via a rights offering to existing shareholders, in a funding “down round” that aims to secure short-term financing. The company’s valuation soared in 2017early 2017 as it looked set to take advantage of genomics advances to fuel improvements in medicine, yet it did not make the progress it expected.
Genomics start-up Human Longevity has seen a further fall in its valuation, with its latest funding round putting its value at $310m, a fall of 80% from its estimated $1.6bn valuation in 2017. The company seeks to pull in $25m via a rights offering to existing shareholders, in a funding “down round” that aims to secure short-term financing. The company’s valuation soared in early 2017 as it looked set to take advantage of genomics advances to fuel improvements in medicine, yet it did not make the progress it expected.